Menu Search
Equities

Q linea AB

3F8:MUN

Q linea AB

Actions
  • Price (EUR)0.1134
  • Today's Change0.00 / 0.00%
  • Shares traded2.00k
  • 1 Year change-60.35%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.

  • Revenue in SEK (TTM)2.27m
  • Net income in SEK-218.33m
  • Incorporated2007
  • Employees97.00
  • Location
    Q linea ABDag Hammarskjolds Vag 52 AUPPSALA 752 37SwedenSWE
  • Phone+46 184443610
  • Websitehttps://www.qlinea.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.